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OBJECTIVES: Warfarin had been the only effective oral anticoagulant (OAC) to 
reduce risk of ischemic stroke in patients with atrial fibrillation (AF) until 
recently new OACs (dabigatran, rivaroxaban and apixaban) became possible 
alternatives for AF patients. Cost-effectiveness of new OACs versus warfarin 
therapy in AF patients was examined. METHODS: A Markov model was designed 
to compare life-long economic and treatment outcomes of apixaban (5mg twice 
daily), dabigatran (150mg twice daily), rivaroxaban (20mg daily), and warfarin 
therapy at anticoagulation care with moderate control on anticoagulation (mean 
time in therapeutic range (TTR) 60.6%) in a hypothetical cohort of AF patients 
aged 65 years old with CHADS2 score 2. Model inputs were derived from 
literature, and outcome measure was incremental cost per quality-adjusted life-
year (QALY) gained (ICER) from the health care provider’s perspective. 
Robustness of model was examined by sensitivity analysis. RESULTS: In the 
base-case scenario, warfarin was the least costly alternative (USD82,768) and it 
gained lowest QALYs (9.571). ICERs of dabigatran and apixaban were USD38,382 
and USD204,787, respectively. Rivaroxaban was more costly and gained less 
QALYs than dabigatran and apixaban. Using USD50,000 as the threshold of 
willingness-to-pay per QALY, dabigatran was the most cost-effective option. The 
most influential factors on the base-case results were the risk of bleeding and 
ischemic stroke of dabigatran comparing to warfarin therapy. In 10,000 Monte 
Carlo simulations, dabigatran was the most likely option to be cost-effective in 
81% of time. CONCLUSIONS: In the present model, the ICER of dabigatran was 
acceptable as the cost-effective alternative when compared to the other new 
OACs and anticoagulation service with moderate anticoagulation control.  
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OBJECTIVES: Estimate the lifetime costs and life-years (LYs) gained associated 
with stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) 
using novel oral anticoagulants (NOACs) apixaban 5 mg, dabigatran 150 mg, and 
rivaroxaban 20 mg relative to warfarin. METHODS: A probabilistic Markov 
decision-analysis model was constructed to evaluate lifetime costs and LYs 
gained for patients receiving NOACs compared to patients receiving adjusted-
dose warfarin. The modeled population was a hypothetical cohort of 70-year old 
patients with NVAF, at an increased risk for stroke (CHADS2≥1), with a renal 
creatinine clearance ≥ 50 mL/min, and no prior contraindications to 
anticoagulation. Rates for clinical events associated with drug efficacy and safety 
were estimated from the RE-LY (dabigatran 150 mg twice daily), ARISTOTLE 
(apixaban 5 mg twice daily), and ROCKET-AF (rivaroxaban 20 mg once daily) 
clinical trials. Medical costs were estimated from a societal perspective and were 
inflated to 2012 US dollars. Sensitivity analyses were conducted to determine 
influential model variables. RESULTS: In the base case, warfarin had the lowest 
cost of $77,843 (standard deviation [SD]: $2,249), followed by rivaroxaban 20 mg 
($78,683±$1,801), dabigatran 150 mg ($82,719±$1,905), and apixaban 5 mg 
($85,350±$1,501). In contrast, warfarin had the highest estimated indirect costs 
($25,485±$58), whereas the estimates were similar for apixaban ($9,499±$6), 
dabigatran ($9,497±$7), and rivaroxaban ($9,514±$6). Apixaban 5 mg yielded the 
highest number of LY’s gained, 13.76 (SD: 0.09), followed by dabigatran 150 mg 
(13.73±0.10), rivaroxaban 20 mg (13.48±0.10), and warfarin (12.98±0.06). The 
model results were dependent upon treatment costs and neurologic events 
associated with rivaroxaban 20 mg. CONCLUSIONS: In patients with NVAF, 
apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were more costly 
alternatives to warfarin but appear to result in a higher number of LYs gained.  
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OBJECTIVES: Resistant hypertension is a difficult condition to treat. More than 
5,000 patients with resistant hypertension have undergone surgery catheter 
based renal denervation (RDN) with good results. The primary objective of this 
study was to estimate the cost-effectiveness of catheter based renal denervation 
(RDN) for resistant arterial hypertension compared with standard of care (SC) in 
Colombia. METHODS: Using a previously validated excel-based Markov model, 
we projected the lifetime effect of RDN or standard of care in direct medical costs 
and outcomes. The model considered 6 health states: stroke, myocardial 
infarction, heart failure, end-stage renal disease, angina and death; The relative 
risk associated with RDN compared to SC for stroke (0.77), Myocardial infarction 
(0.74-0.90), Heart Failure (0.73) and end-stage renal disease (0.87) were extracted 
from the literature and converted into transition probabilities. Costs for drugs, 
procedures and other health care resources were obtained from local sources, 
and private and official databases. Life expectancy data was imputed from the 
WHO’s life tables and the utilities for each health state were derived from the 
literature. The analysis was performed using the payer perspective and used an 
annual discount for cost and outcomes of 3%. RESULTS: In our simulation, 
subjects undergoing RDN achieved higher QALY’s (10.27 vs. 9.72) at a higher cost 
during their lifetime (COP$91.406.781 vs. COP$80.799.285). The main drivers for 
these differences were the reduction in complications in the group of subject 
treated with RDN and the costs of treatment. These differences yielded and ICER 
of COP$19.301.843. CONCLUSIONS: Catheter based RDN compared with standard 
care appears to be a favorable strategy for resistant arterial hypertension in 
Colombia, resulting in lower cardiovascular morbidity and mortality and 
decreased renal complications.  
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OBJECTIVES: Atrial Fibrillation (AF) is the most common sustained cardiac 
arrhythmia affecting approximately 40,000 to 80,000 inhabitants in Costa Rica. 
AF increases stroke, thrombo-embolism, deaths, heart failure and 
hospitalizations rates, affecting the quality of life and raising overall costs. 
Literature suggests anticoagulation is the best strategy to prevent strokes and 
reduce death rates in AF. The aim of this study was to assess the cost-
effectiveness (CE) of warfarin against Apixaban, Rivaroxaban, and Dabigatran as 
therapy for AF, from the public health care perspective. METHODS: A simulated 
cohort of patients with AF entered a decision-tree model to compare costs and 
effectiveness of Warfarin (5 mg/day) (comparator), Apixaban (5 mg/12 hours), 
Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 
mg/day). Effectiveness measures were: stroke, bleeding and myocardial 
infarction (MI) rates and deaths. The model used a lifetime horizon and only 
direct medical costs were considered (inpatient costs, medication expenses, 
adverse events costs, tests). Effectiveness and epidemiologic data were retrieved 
from published literature. Local costs (US$ 2012) were gathered from the Social 
Security of Costa Rica official databases. RESULTS: Apixaban resulted as the less 
expensive option for AF in adult patients and it was the only treatment that 
consistently prevented all three considered diseases: Three MIs, 18 strokes, 54 
bleedings avoided when compared to Warfarin. Mortality rate was found to be 
similar with all strategies implemented. Overall costs were US$43,211,440.23 for 
warfarin, US$38,240,522.33 for Apixaban (lowest), US$38,458,665.03 for 
Dabigatran 110 mg, US$41,055,937.68 for Dabigatran 150 mg, and 
US$42,551,663.86 for Rivaroxaban. In the CE incremental analysis, Apixaban 
appeared as a cost-saving option. Apixaban obtained the highest probability of 
being cost-effective with a 3 GPB per capita in Costa Rica. PSA results support the 
robustness of these findings. CONCLUSIONS: Apixaban resulted as the cost-
saving therapy for AF adult patients in Costa Rica.  
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OBJECTIVES: The aim of the study was to demonstrate the cost effectiveness and 
cost utility of Ivabradine (Procoralan®) in the treatment of patients with Chronic 
Heart Failure (CHF) in Mexico, from the institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness and cost utility of 2 
competing strategies in the treatment of patients with CHF using the results of 
SHIFT study: 1) Ivabradine plus standard care and 2) standard care. A Markov 
model was developed, the model considers two base case analyses; 29 months 
and extrapolated lifetime. The outcome measure was life years gained (LY) and 
quality adjusted life years (QALY), also incremental cost effectiveness ratio (ICER) 
was performed. Direct health care cost where used and the discount rate was of 
5%. The sensitivity analysis was carrying out in four time horizons: 29 months, 5 
years, 10 years and lifetime. Probabilistic sensitivity analysis was performed. 
RESULTS: Ivabradine plus standard care had more efficacy and less cost in the 
treatment of CHF. The incremental LY and QALY were 0.16 and 0.20, respectively 
on the 29 months analysis and 0.036 and 0.037, respectively for the lifetime 
horizon. The incremental cost using Ivabradine plus standard care was -$37,821 
in the 29 months’ time horizon, while in the lifetime horizon was -$53,710 for 
each LY and QALY. The sensitivity analyses proved that Ivabradine plus 
standard care was cost effective compared to standard care. According to the 
probabilistic sensitivity analyses, the likelihood of Ivabradine plus standard care 
to be cost effective is 100% under the willingness-to-pay threshold in Mexico. 
CONCLUSIONS: evidence from the clinical and the cost effectiveness study prove 
that the use of Ivabradine plus standard care in the treatment of patients with 
CHF is cost effective, and must be considered as first option in the treatment of 
patients with CHF diagnosis.  
 
PCV85  
COST EFFECTIVENESS OF ZOFENOPRIL IN PATIENTS WITH LEFT VENTRICULAR 
SYSTOLIC DYSFUNCTION AFTER ACUTE MYOCARDIAL INFARCTION:  
A POST- HOC ANALYSIS OF THE SMILE-4 STUDY  
Borghi C1, Ambrosioni E1, Omboni S2, Cicero AFG1, Bacchelli S1, Degli Esposti D1, Novo S3, 
Vinereanu D4, Ambrosio G5, Reggiardo G6, Zava D6 
1Policlinico S. Orsola, University of Bologna, Bologna, Italy, 2Italian Institute of Telemedicine, 
Solbiate Arno, Italy, 3University of Palermo, Palermo, Italy, 4University and Emergency Hospital, 
Bucharest, Romania, 5University of Perugia, Perugia, Italy, 6Istituto Lusofarmaco d'Italia S.p.A., 
Peschiera Borromeo, Italy  
